Advertisement
U.S. markets open in 2 hours 36 minutes
  • S&P Futures

    5,306.25
    -2.00 (-0.04%)
     
  • Dow Futures

    40,143.00
    -1.00 (-0.00%)
     
  • Nasdaq Futures

    18,495.00
    -8.75 (-0.05%)
     
  • Russell 2000 Futures

    2,136.60
    -1.80 (-0.08%)
     
  • Crude Oil

    82.08
    +0.73 (+0.90%)
     
  • Gold

    2,231.30
    +18.60 (+0.84%)
     
  • Silver

    24.83
    +0.08 (+0.32%)
     
  • EUR/USD

    1.0793
    -0.0036 (-0.33%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.98
    +0.20 (+1.56%)
     
  • GBP/USD

    1.2620
    -0.0018 (-0.14%)
     
  • USD/JPY

    151.3810
    +0.1350 (+0.09%)
     
  • Bitcoin USD

    70,598.74
    +608.52 (+0.87%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,954.79
    +22.81 (+0.29%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

FINAL DEADLINE APPROACHING: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Kadmon Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / May 11, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Kadmon Holdings, Inc. ("Kadmon" or "the Company") (NASDAQ:KDMN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between October 1, 2020 and March 10, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before June 2, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Kadmon submitted a New Drug Application ("NDA") for belumosudil for the treatment of cGVHD to the FDA that was incomplete and deficient. When the Company submitted additional data to the FDA in response to the agency's request, it materially changed the NDA submission. The FDA was likely to extend the Prescription Drug User Fee Act ("PDUFA") target action date to review the Company's NDA. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Kadmon, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE: The Schall Law Firm



View source version on accesswire.com:
https://www.accesswire.com/646488/FINAL-DEADLINE-APPROACHING-The-Schall-Law-Firm-Reminds-Investors-of-a-Class-Action-Lawsuit-Against-Kadmon-Holdings-Inc-and-Encourages-Investors-with-Losses-to-Contact-the-Firm

Advertisement